Comparison of dose-dense and every-3-week taxane in the neoadjuvant treatment of ovarian, fallopian tube, and primary peritoneal cancer

Hinchcliff, Emily

105
Comparison of dose-dense and every-3-week taxane in the neoadjuvant treatment of ovarian, fallopian tube, and primary peritoneal cancer

Sunday, March 29, 2015: 3:05 PM

Salon C-D (Hilton Chicago)

E. M. Hinchcliff¹, I. Wilkinson-Ryan², A. A. Gockley³, K. M. Esselen¹, A. R. Hagemann², M. Auer⁴, Y. Tao⁵, D. G. Mutch², K. C. Fuh⁶ and N. S. Horowitz⁷
¹Brigham and Women's Hospital/Harvard University, Boston, MA, ²Washington University School of Medicine, St. Louis, MO, ³Massachusetts General Hospital, Boston, MA, ⁴The Cleveland Clinic Foundation, Cleveland, OH, ⁵Washington University School of Medicine, St Louis, MO, ⁶Stanford University, Stanford, CA, ⁷Harvard University, Boston, MA

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

105
Comparison of dose-dense and every-3-week taxane in the neoadjuvant treatment of ovarian, fallopian tube, and primary peritoneal cancer

105 Comparison of dose-dense and every-3-week taxane in the neoadjuvant treatment of ovarian, fallopian tube, and primary peritoneal cancer

105
Comparison of dose-dense and every-3-week taxane in the neoadjuvant treatment of ovarian, fallopian tube, and primary peritoneal cancer